pyrroles has been researched along with Lymphangioleiomyomatosis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, KQ; Li, C; Liu, S; Sui, X; Tang, MW; Tian, XL; Xu, KF; Xu, WS | 1 |
Atochina-Vasserman, EN; Goncharov, DA; James, ML; Krymskaya, VP; Milavec, M; Volgina, AV | 1 |
2 other study(ies) available for pyrroles and Lymphangioleiomyomatosis
Article | Year |
---|---|
Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.
Topics: Acquired Hyperostosis Syndrome; Adult; Female; Humans; Janus Kinase 3; Lymphangioleiomyomatosis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
Topics: Animals; Atorvastatin; Caspase 3; Cell Line; Cell Proliferation; Cell Shape; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Humans; Lymphangioleiomyomatosis; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Simvastatin; Sirolimus; TOR Serine-Threonine Kinases; Transfection; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2013 |